Study of Placental Inflammation in Gestational Diabetes
Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Mar 18, 2025
Trial Information
Current as of April 23, 2025
Active, not recruiting
Keywords
ClinConnect Summary
The aim of this study is to investigate systemic and placental inflammation in women with gestational diabetes mellitus, in particular the role of inflammasome NLRP3 and the chemokine scavenger decoy receptor D6, compared to women with uncomplicated pregnancy
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women with gestational diabetes mellitus
- • Women with uncomplicated pregnancy
- • Age \>18 years
- • Singleton pregnancy
- Exclusion Criteria:
- • Age \< 18 years
- • Infections (HIV,HCV)
- • Multiple pregnancy
- • Cancer
Trial Officials
Chiara Tersigni
Principal Investigator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
About Fondazione Policlinico Universitario Agostino Gemelli Irccs
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is a leading research and healthcare institution based in Rome, Italy, renowned for its commitment to advancing medical science and improving patient care. As a prominent academic medical center affiliated with the Catholic University of the Sacred Heart, it integrates clinical practice, education, and research, fostering innovation in various fields of medicine. The foundation conducts a wide range of clinical trials aimed at developing new therapies and enhancing treatment protocols, with a focus on translational research that bridges the gap between laboratory discoveries and patient care. Its multidisciplinary approach and dedication to high ethical standards position it as a key player in the landscape of clinical research and healthcare improvement in Italy and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rome, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported